JHP Pharmaceuticals, LLC
In 2012, Warburg Pincus invested in JHP Pharmaceuticals (JHP), a manufacturer of sterile injectable drugs which require a complex and technically demanding manufacturing process. In its branded genetics segment, JHP manufactures and distributes branded injectable drugs to hospitals and long-term care facilities in the U.S., while in its contract manufacturing segment, JHP manufactures sterile injectable drugs for other pharmaceutical companies. The Warburg Pincus team believed that JHP was an attractive platform with an embedded pipeline upon which the team could build a large drug company in the growing U.S. generic injectable drug market. JHP’s large-scale sterile manufacturing facility was highly strategic and differentiated in an area where there was a supply-demand imbalance for sterile drug production capacity. During Warburg Pincus’ hold period, JHP enjoyed strong financial performance, driven by new product launches and strong performance of its existing products. JHP also strengthened its pipeline by adding nine new products and opening a laboratory facility to bolster its research and development capabilities. Warburg Pincus worked closely with JHP to build an industry-leading management team and Board of Directors, including the addition of two board members and a new CFO and VP of Manufacturing. In 2014, Warburg Pincus exited JHP through a sale to a subsidiary of Par Pharmaceutical Companies, Inc.
Website Case Studies Disclaimer
The investments described in the case studies are provided for illustrative purposes only and are not, and do not purport to be, representative of all investments, or all types of investments, previously made by Warburg Pincus, or indicative of the performance of all prior Warburg Pincus investments. The case studies have been selected on the basis of objective criteria that Warburg Pincus believes are representative of the firm’s experience partnering with portfolio company management teams, and of the sectors, stages, strategies and/or geographies in which the firm invests. The information provided in the case studies are not necessarily an indication of future results, and may not be relied up for any purpose. Warburg Pincus’ current or future portfolio companies may differ materially in size, type, performance and other characteristics from the investments presented in the case studies. Further, references in this case study should not be construed as a recommendation or offer to buy or sell any particular security or to make any particular investment.